CytomX Therapeutics Inc (CTMX)
1.69
+0.02
(+1.20%)
USD |
NASDAQ |
Apr 23, 12:14
CytomX Therapeutics Total Liabilities (Quarterly): 249.24M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 249.24M |
| September 30, 2023 | 272.40M |
| June 30, 2023 | 294.21M |
| March 31, 2023 | 321.27M |
| December 31, 2022 | 346.64M |
| September 30, 2022 | 198.02M |
| June 30, 2022 | 211.38M |
| March 31, 2022 | 228.63M |
| December 31, 2021 | 339.87M |
| September 30, 2021 | 259.56M |
| June 30, 2021 | 271.49M |
| March 31, 2021 | 288.14M |
| December 31, 2020 | 366.44M |
| September 30, 2020 | 327.12M |
| June 30, 2020 | 343.65M |
| March 31, 2020 | 366.90M |
| December 31, 2019 | 290.17M |
| September 30, 2019 | 290.44M |
| Date | Value |
|---|---|
| June 30, 2019 | 303.78M |
| March 31, 2019 | 321.94M |
| December 31, 2018 | 326.22M |
| September 30, 2018 | 325.06M |
| June 30, 2018 | 335.81M |
| March 31, 2018 | 326.82M |
| December 31, 2017 | 327.75M |
| September 30, 2017 | 341.56M |
| June 30, 2017 | 299.62M |
| March 31, 2017 | 104.10M |
| December 31, 2016 | 120.65M |
| September 30, 2016 | 103.46M |
| June 30, 2016 | 105.67M |
| March 31, 2016 | 79.24M |
| December 31, 2015 | 71.15M |
| September 30, 2015 | 230.83M |
| June 30, 2015 | 70.49M |
| December 31, 2014 | 151.60M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
198.02M
Minimum
Sep 2022
366.90M
Maximum
Mar 2020
293.12M
Average
290.44M
Median
Sep 2019
Total Liabilities (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | 7.107B |
| Sarepta Therapeutics Inc | 2.405B |
| Puma Biotechnology Inc | 177.09M |
| Ocular Therapeutix Inc | 160.93M |
| Bristol-Myers Squibb Co | 65.67B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 201.79M |
| Shareholders Equity (Quarterly) | -47.45M |
| Current Ratio | 1.173 |